Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982358 | 0.84 | MEN1 (0.54) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL27462408 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL468298 | 0.79 | LMNA (0.52) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL6394938 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10993059 | 0.77 | HTR1A (0.46) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL27474102 | 0.76 | LMNA (0.58) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL26978217 | 0.75 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14399666 | 0.74 | HTR2A (0.53) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10991862 | 0.74 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4224310 | 0.73 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085582-A1 | PROTEIN CAGES | THE UNIVERSITY OF SYDNEY (AU) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12605425-B2 | TNF muteins and uses thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-04-21 | — | — | US | disclosed |
| EP-4710935-A2 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | Aravax Pty Ltd (AU) | 2026-03-18 | — | — | EP | disclosed |
| EP-3980085-B1 | COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION | UNIV RAMOT (IL) | 2026-03-11 | — | — | EP | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260049121-A1 | SUPRAMOLECULAR HIGH AFFINITY PROTEIN-BINDING SYSTEM FOR PURIFICATION OF BIOMACROMOLECULES | UNIV JOHNS HOPKINS (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250345412-A1 | Coronavirus Vaccine | The Univesity of Melbourne Grattan Street (AU) | 2025-11-13 | — | — | US | disclosed |
| US-20220088159-A1 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | ARAVAX PTY LTD. (AU) | 2022-03-24 | — | — | US | disclosed |
| US-11273201-B2 | Compositions and methods for inducing thrombopoiesis | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2022-03-15 | — | — | US | disclosed |
| US-11266737-B2 | Immunotherapeutic composition and uses thereof | ARAVAX PTY LTD (AU) | 2022-03-08 | — | — | US | disclosed |
| US-20220049236-A1 | COMPOSITIONS COMPRISING THE PROPEPTIDE OF LYSYL OXIDASE AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-02-17 | — | — | US | disclosed |
| US-11246908-B2 | Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-15 | — | — | US | disclosed |
| US-11246907-B2 | Immunosuppressive agents and their use in therapy | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NO) | 2022-02-15 | — | — | US | disclosed |
| WO-2022032175-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-11229614-B2 | Supramolecular hydrogel applications to the carotid bodies to treat hypertension and sleep apnea in obesity | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-01-25 | — | — | US | disclosed |
| US-4492694-A | ORAL ADMINISTRATION | ELI LILLY AND COMPANY (US) | 1985-01-08 | — | — | US | disclosed |
| EP-0122157-A2 | Improvements in or relating to indolylglycyl cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605425-B2 | TNF muteins and uses thereof | TNFRSF1A, TNF, TNFSF11 | ALDH1A1 4618/4885MEN1 119/4885KMT2A 3244/4885 |
| US-11229614-B2 | Supramolecular hydrogel applications to the carotid bodies to treat hypertension and sleep apnea in obesity | TRPM7, TRPC7, TRPM4 | ALDH1A1 4107/4885MEN1 572/4885KMT2A 2366/4885 |
| US-20260049121-A1 | SUPRAMOLECULAR HIGH AFFINITY PROTEIN-BINDING SYSTEM FOR PURIFICATION OF BIOMACROMOLECULES | IL33, MAX, HM13 | ALDH1A1 4867/4885MEN1 2898/4885KMT2A 1961/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | ALDH1A1 3922/4885MEN1 4679/4885KMT2A 1692/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | ALDH1A1 2964/4885MEN1 3799/4885KMT2A 1639/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | ALDH1A1 733/4885MEN1 2494/4885KMT2A 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.